<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97600">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02104557</url>
  </required_header>
  <id_info>
    <org_study_id>A6791036</org_study_id>
    <nct_id>NCT02104557</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance Study For Sayana®</brief_title>
  <acronym>SAYANA</acronym>
  <official_title>Post Marketing Surveillance To Observe Safety And Efficacy Of Sayana® Used For Contraception And Management Of Endometriosis-Associated Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post Marketing Surveillance To Observe Safety And Efficacy Of Sayana® Used For Contraception
      And Management Of Endometriosis-Associated Pain
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post Marketing Surveillance required by Korea MFDS regulation. Select among patients who
      randomly visit the site who meet the inclusion/exclusion criteria.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Cumulative percent of patients who become pregnant over the 6 month observation period and rate of pregnancies per 100 person-years of follow-up</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The patient response to endometriosis pain treatment: endometriosis pain treatment effect will be measured by visual analogue scale scores recorded by the subjects at each visit.</measure>
    <time_frame>3 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>The subject will be asked to indicate the subjective level of endometriosis pain looking back at the last 3 months and mark it with a single vertical mark on the 100mm horizontal visual analogue scale, where 0 mm represents absence of pain and 100mm indicates unbearable pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events categorized according to physical organ and disease/symptom.</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Product Surveillance, Postmarketing</condition>
  <arm_group>
    <arm_group_label>prevention of pregnancy</arm_group_label>
    <description>Non intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>management of endometriosis-associated pain</arm_group_label>
    <description>Non intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non intervention</intervention_name>
    <description>Non intervention</description>
    <arm_group_label>prevention of pregnancy</arm_group_label>
    <other_name>Non intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non intervention</intervention_name>
    <description>Non intervention</description>
    <arm_group_label>management of endometriosis-associated pain</arm_group_label>
    <other_name>Non intervention</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women subjects who are initiating treatment with Sayana® for the first time as per the
        local product document for usage
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Subjects or legally authorized representatives of pediatric subjects agree to provide
        written informed consent form (ie, data privacy statement).

        2.Women subjects who are initiating treatment with Sayana® for the first time as per the
        local product document for usage

        Exclusion Criteria:

          -  Known or suspected pregnancy.

          -  Undiagnosed vaginal bleeding.

          -  Known or suspected malignancy of breast.

          -  Active thrombophlebitis, or current or past history of thromboembolic disorders, or
             cerebral vascular disease.

          -  Significant liver disease.

          -  Known hypersensitivity to medroxyprogesterone acetate or any of its other
             ingredients.

          -  Women who are before menarche or who are post-menopausal.

          -  Treatment with any investigational agent or device within 30 days prior to the
             enrollment visit.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Sanborn jeil Women's Hospital</name>
      <address>
        <city>Gunpo-si</city>
        <state>Gyeonggi-Do</state>
        <zip>435-849</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor Ewha Obgyn Clinic</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-811</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cheong Wha Wonen's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-806</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nana Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>137-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roen Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>135-932</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6791036&amp;StudyName=Post%20Marketing%20Surveillance%20Study%20For%20Sayana%AE</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sayana</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Contraception</keyword>
  <keyword>Endometriosis-associated pain</keyword>
  <keyword>PMS</keyword>
  <keyword>Post Marketing Surveillance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
